Literature DB >> 23037921

44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?

E Koumarianou1, N S Loktionova, M Fellner, F Roesch, O Thews, D Pawlak, S C Archimandritis, R Mikolajczak.   

Abstract

AIM: In the present study we demonstrate the in vitro and in vivo comparison of the (44)Sc and (68)Ga labeled DOTA-BN[2-14]NH(2). (44)Sc is a positron emitter with a half life of 3.92 h. Hence it could be used for PET imaging with ligands requiring longer observation time than in the case of (68)Ga.
METHODS: The binding affinity of (nat)Sc-DOTA-BN[2-14]NH(2) and (nat)Ga-DOTA-BN[2-14]NH(2) to GRP receptors was studied in competition to [(125)I-Tyr(4)]-Bombesin in the human prostate cancer cell line PC-3. A preliminary biodistribution in normal rats was performed, while first microPET images were assessed in male Copenhagen rats bearing the androgen-independent Dunning R-3327-AT-1 prostate cancer tumor.
RESULTS: The affinity to GRP receptors in the PC-3 cell line was higher for (nat)Ga-DOTA-BN[2-14]NH(2) (IC(50)(nM)=0.85 ± 0.06) than that of (nat)Sc-DOTA-BN[2-14]NH(2) (IC(50) (nM)=6.49 ± 0.13). The internalization rate of (68)Ga labeled DOTA-BN[2-14]NH(2) was slower than that of (44)Sc, but their final internalization percents were comparable. (68)Ga-DOTA-BN[2-14]NH(2) was externalized faster than (44)Sc-DOTA-BN[2-14]NH(2). The biodistribution of (44)Sc-DOTA-BN[2-14]NH(2) and (68)Ga-DOTA-BN[2-14]NH(2) in normal rats revealed a higher uptake in target organs and tissues of the first one while both excreted mainly through urinary tract. In microPET images both tracers were accumulated in the tumor with similar uptake patterns.
CONCLUSIONS: Despite the differences in the receptor affinity both the (68)Ga- and the (44)Sc-labeled DOTA-BN[2-14]NH(2) tracers showed comparable distribution and similar time constants of uptake and elimination. Moreover no differences in tumor accumulation (neither in the overall uptake nor in the dynamics) were observed from the microPet imaging. From that perspective the use of either (44)Sc or (68)Ga for detecting tumors with GRP receptors is equivalent.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23037921     DOI: 10.1016/j.apradiso.2012.08.004

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  12 in total

1.  Separation of cyclotron-produced 44Sc from a natural calcium target using a dipentyl pentylphosphonate functionalized extraction resin.

Authors:  H F Valdovinos; R Hernandez; T E Barnhart; S Graves; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2014-10-08       Impact factor: 1.513

Review 2.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

3.  In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57.

Authors:  Johan Hygum Dam; Birgitte Brinkmann Olsen; Christina Baun; Poul-Flemming Høilund-Carlsen; Helge Thisgaard
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

Review 4.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

Review 5.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

6.  Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment.

Authors:  Rubel Chakravarty; Shreya Goel; Hector F Valdovinos; Reinier Hernandez; Hao Hong; Robert J Nickles; Weibo Cai
Journal:  Bioconjug Chem       Date:  2014-11-24       Impact factor: 4.774

7.  44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations.

Authors:  Katharina A Domnanich; Cristina Müller; Renata Farkas; Raffaella M Schmid; Bernard Ponsard; Roger Schibli; Andreas Türler; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2016-05-05

8.  Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.

Authors:  Piotr F J Lipiński; Piotr Garnuszek; Michał Maurin; Raphael Stoll; Nils Metzler-Nolte; Artur Wodyński; Jan Cz Dobrowolski; Marta K Dudek; Monika Orzełowska; Renata Mikołajczak
Journal:  EJNMMI Res       Date:  2018-04-16       Impact factor: 3.138

9.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

10.  (44)Sc: an attractive isotope for peptide-based PET imaging.

Authors:  Reinier Hernandez; Hector F Valdovinos; Yunan Yang; Rubel Chakravarty; Hao Hong; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2014-07-23       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.